Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

Biological Psychiatry

Volumn 84, Issue 6, 2018, Pages 433-442

  Plavén Sigray, Pontus ^a   Matheson, Granville J ^a   Collste, Karin ^a   Ashok, Abhishekh H ^b,c,d   Coughlin, Jennifer M ^e   Howes, Oliver D ^b,c,d   Mizrahi, Romina ^f   Pomper, Martin G ^e   Rusjan, Pablo ^f   Veronese, Mattia ^b   Wang, Yuchuan ^e   Cervenka, Simon ^a  

^a STOCKHOLM COUNTY COUNCIL   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Immune activation; Meta analysis; Microglia; Positron emission tomography; Psychosis; Schizophrenia; Translocator protein

Indexed keywords

CARRIER PROTEIN; RADIOLIGAND; 4 AMINOBUTYRIC ACID RECEPTOR; BIOLOGICAL MARKER; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TSPO PROTEIN, HUMAN;

ARTICLE; BRAIN REGION; DATA ANALYSIS; FRONTAL CORTEX; GLIA CELL; HIPPOCAMPUS; HUMAN; IMMUNOCOMPETENT CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TEMPORAL CORTEX; BAYES THEOREM; BRAIN; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; FEMALE; GLIA; MALE; META ANALYSIS; METABOLISM; MICROGLIA; PATHOLOGY;

BAYES THEOREM; BIOMARKERS; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICROGLIA; NEUROGLIA; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTORS, GABA; SCHIZOPHRENIA;

EID: 85045118862     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2018.02.1171     Document Type: Article

References (74)

1. Arias, I., Sorlozano, A., Villegas, E., de Dios Luna, J., McKenney, K., Cervilla, J., et al. Infectious agents associated with schizophrenia: A meta-analysis. Schizophr Res 136 (2012), 128–136.
2. Ripke, S., Neale, B.M., Pers, T.H., Julià A., Kahn, R.S., Kalaydjieva, L., Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (2014), 421–427.
3. Upthegrove, R., Manzanares-Teson, N., Barnes, N.M., Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis. Schizophr Res 155 (2014), 101–108.
4. Akhondzadeh, S., Tabatabaee, M., Amini, H., Abhari, S.A.A., Abbasi, S.H., Behnam, B., Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 90 (2007), 179–185.
5. Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121 (2010), 118–124.
6. Rapaport, M.H., Delrahim, K.K., Bresee, C.J., Maddux, R.E., Ahmadpour, O., Dolnak, D., Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 57 (2005), 1594–1596.
7. Ory, D., Planas, A., Dresselaers, T., Gsell, W., Postnov, A., Celen, S., et al. PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nucl Med Biol 42 (2015), 753–761.
8. Toth, M., Little, P., Arnberg, F., Mulder, J., Halldin, C., Ha, J., Holmin, S., Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: Longitudinal positron emission tomography and immunofluorescent tracking. Brain Struct Funct 221 (2016), 1279–1290.
9. Venneti, S., Lopresti, B.J., Wiley, C.A., Molecular imaging of microglia/macrophages in the brain. Glia 61 (2013), 10–23.
10. Doorduin, J., De Vries, E.F.J., Willemsen, A.T.M., De Groot, J.C., Dierckx, R.A., Klein, H.C., Neuroinflammation in schizophrenia-related psychosis: A PET study. J Nucl Med 50 (2009), 1801–1807.
11. 11 C]PK11195 positron emission tomography study. Biol Psychiatry 64 (2008), 820–822.
12. 11 C](R)-PK11195 binding to TSPO in the human brain—A PET study in control subjects. EJNMMI Res, 2, 2012, 15.
13. Slifstein, M., Laruelle, M., Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 28 (2001), 595–608.
14. Varnäs, K., Varrone, A., Farde, L., Modeling of PET data in CNS drug discovery and development. J Pharmacokinet Pharmacodyn 40 (2013), 267–279.
15. 11 C](R)-PK11195 positron emission tomography study. Mol Psychiatry 21 (2016), 1672–1679.
16. 11 C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. NPJ Schizophr, 2, 2016, 16031.
17. Di Biase, M.A., Zalesky, A., O'Keefe, G., Laskaris, L., Baune, B.T., Weickert, C.S., et al. PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia. Transl Psychiatry, 7, 2017, e1225.
18. 11 C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176—Based on recent publications that measured specific-to-non-displaceable ratios. EJNMMI Res, 7, 2017, 84.
19. 11 C-(R)-PK11195. J Cereb Blood Flow Metab 38 (2018), 393–403.
20. 11 C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage 49 (2010), 2924–2932.
21. 18 F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol 35 (2008), 305–314.
22. 11 C]PBR28 PET brain imaging study. Am J Psychiatry 173 (2016), 44–52.
23. 11 C]PBR28. Mol Psychiatry 22 (2017), 850–856.
24. 11 C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry, 6, 2016, e777.
25. 18 F]FEPPA. Am J Psychiatry 174 (2017), 118–124.
26. 18 F]-FEPPA. Schizophr Bull 41 (2015), 85–93.
27. 11 C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging 43 (2016), 173–183.
28. Kreisl, W.C., Jenko, K.J., Hines, C.S., Lyoo, C.H., Corona, W., Morse, C.L., et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 33 (2013), 53–58.
29. Owen, D.R., Yeo, A.J., Gunn, R.N., Song, K., Wadsworth, G., Lewis, A., et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32 (2012), 1–5.
30. Owen, D.R.J., Gunn, R.N., Rabiner, E.A., Bennacef, I., Fujita, M., Kreisl, W.C., et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 52 (2011), 24–32.
31. Drzyzga, Ł., Obuchowicz, E., Marcinowska, A., Herman, Z.S., Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20 (2006), 532–545.
32. Stewart, L.A., Clarke, M., Rovers, M., Riley, R.D., Simmonds, M., Stewart, G., Tierney, J.F., Preferred reporting items for a systematic review and meta-analysis of individual participant data: The PRISMA-IPD statement. JAMA 313 (2015), 1657–1665.
33. 11 C]DAA1106 for PET: An imaging tool for glial cells in the brain. Synapse 52 (2004), 283–291.
34. Vehtari, A., Gelman, A., Gabry, J., Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat Comput 27 (2017), 1413–1432.
35. Jeffreys, H., Theory of Probability, 3rd ed. 1961, Oxford University Press, Oxford, UK.
36. Kass, R.E., Raftery, A.E., Bayes factors. J Am Stat Assoc 90 (1995), 773–795.
37. Morey, R.D., Wagenmakers, E.-J., Simple relation between Bayesian order-restricted and point-null hypothesis tests. Statist Probab Lett 92 (2014), 121–124.
38. Cohen, J., Statistical Power Analysis for the Behavioral Sciences, 2nd ed. 1998, Lawrence Erbaum, Hillsdale, NJ.
39. Dienes, Z., Using Bayes to get the most out of non-significant results. Front Psychol, 5, 2014, 781.
40. Gelman, A., Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper). Bayesian Anal 1 (2006), 515–534.
41. Carpenter, B., Gelman, A., Hoffman, M., Lee, D., Goodrich, B., Betancourt, M., et al. Stan: A probabilistic programming language. J Stat Softw, 76, 2017.
42. Buerkner, P.-C., brms: An R package for Bayesian multilevel models using Stan. J Stat Softw 80 (2016), 1–28.
43. Bates, D., Mächler, M., Bolker, B., Walker, S., Fitting linear mixed-effects models using lme4. J Stat Softw 67 (2015), 1–48.
44. Kalk, N.J., Owen, D.R., Tyacke, R.J., Reynolds, R., Rabiner, E.A., Lingford-Hughes, A.R., Parker, C.A., Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?. Synapse 67 (2013), 909–912.
45. Monji, A., Kato, T.A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 42 (2013), 115–121.
46. Danovich, L., Veenman, L., Leschiner, S., Lahav, M., Shuster, V., Weizman, A., Gavish, M., The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur Neuropsychopharmacol 18 (2008), 24–33.
47. Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol Psychiatry 70 (2011), 663–671.
48. Howes, O.D., McCutcheon, R., Inflammation and the neural diathesis-stress hypothesis of schizophrenia: A reconceptualization. Transl Psychiatry, 7, 2017, e1024.
49. Mizrahi, R., Social stress and psychosis risk: Common neurochemical substrates?. Neuropsychopharmacology 41 (2016), 666–674.
50. Laskaris, L.E., Di Biase, M.A., Everall, I., Chana, G., Christopoulos, A., Skafidas, E., et al. Microglial activation and progressive brain changes in schizophrenia. Br J Pharmacol 173 (2016), 666–680.
51. Trépanier, M.O., Hopperton, K.E., Mizrahi, R., Mechawar, N., Bazinet, R.P., Postmortem evidence of cerebral inflammation in schizophrenia: A systematic review. Mol Psychiatry 21 (2016), 1009–1026.
52. van Kesteren, C., Gremmels, H., de Witte, L.D., Hol, E.M., Van Gool, A.R., Falkai, P.G., et al. Immune involvement in the pathogenesis of schizophrenia: A meta-analysis on postmortem brain studies. Transl Psychiatry, 7, 2017, e1075.
53. Lavisse, S., Guillermier, M., Hérard, A.-S., Petit, F., Delahaye, M., Van Camp, N., et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 32 (2012), 10809–10818.
54. Kurumaji, A., Wakai, T., Toru, M., Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J Neural Transm 104 (1997), 1361–1370.
55. Notter, T., Coughlin, J.M., Gschwind, T., Weber-Stadlbauer, U., Wang, Y., Kassiou, M., et al. Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Mol Psychiatry 23 (2018), 323–334.
56. Liddelow, S.A., Guttenplan, K.A., Clarke, L.E., Bennett, F.C., Bohlen, C.J., Schirmer, L., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541 (2017), 481–487.
57. Prinz, M., Priller, J., Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease. Nat Rev Neurosci 15 (2014), 300–312.
58. Narayan, N., Mandhair, H., Smyth, E., Dakin, S.G., Kiriakidis, S., Wells, L., et al. The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory “M1” human macrophages. PLoS One, 12, 2017, e0185767.
59. Owen, D.R., Narayan, N., Wells, L., Healy, L., Smyth, E., Rabiner, E.A., et al. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. J Cereb Blood Flow Metab 37 (2017), 2679–2690.
60. Forsberg, A., Cervenka, S., Jonsson Fagerlund, M., Rasmussen, L.S., Zetterberg, H., Erlandsson Harris, H., et al. The immune response of the human brain to abdominal surgery. Ann Neurol 81 (2017), 572–582.
61. Banati, R.B., Middleton, R.J., Chan, R., Hatty, C.R., Kam, W.W.-Y., Quin, C., et al. Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat Commun, 5, 2014, 5452.
62. Ryu, J.K., Choi, H.B., McLarnon, J.G., Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol Dis 20 (2005), 550–561.
63. Leaver, K.R., Reynolds, A., Bodard, S., Guilloteau, D., Chalon, S., Kassiou, M., Effects of translocator protein (18 kDa) ligands on microglial activation and neuronal death in the quinolinic-acid-injected rat striatum. ACS Chem Neurosci 3 (2012), 114–119.
64. Wang, W., Zhang, L., Zhang, X., Xue, R., Li, L., Zhao, W., et al. Lentiviral-mediated overexpression of the 18 kDa translocator protein (TSPO) in the hippocampal dentate gyrus ameliorates LPS-induced cognitive impairment in mice. Front Pharmacol, 7, 2016, 384.
65. 3 H]PK 11195: Anatomical and subcellular distribution. Brain Res Bull 18 (1987), 49–61.
66. 11 C]PBR28 binding potential in vivo: A first human TSPO blocking study. J Cereb Blood Flow Metab 34 (2014), 989–994.
67. 11 C-PBR28 imaging in multiple sclerosis patients and healthy controls: Test–retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging 42 (2015), 1081–1092.
68. 18 F]FEPPA. Neuropsychopharmacology 42 (2017), 2474–2481.
69. 11 C]PBR28 data. EJNMMI Res, 7, 2017, 58.
70. 11 C]PBR28 for 18kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis. J Cereb Blood Flow Metab 38 (2018), 1227–1242.
71. Zhang, M., Liu, J., Zhou, M.-M., Wu, H., Hou, Y., Li, Y.-F., et al. Elevated neurosteroids in the lateral thalamus relieve neuropathic pain in rats with spared nerve injury. Neurosci Bull 32 (2016), 311–322.
72. Cumming, P., Burgher, B., Patkar, O., Breakspear, M., Vasdev, N., Thomas, P., et al. Sifting through the surfeit of neuroinflammation tracers. J Cereb Blood Flow Metab 38 (2017), 204–224.
73. Tudur Smith, C., Marcucci, M., Nolan, S.J., Iorio, A., Sudell, M., Riley, R., et al. Individual participant data meta-analyses compared with meta-analyses based on aggregate data. Cochrane Database Syst Rev 2016 Sep 6, 9, 2016, MR000007.
74. Van Erp, T.G.M., Preda, A., Nguyen, D., Faziola, L., Turner, J., Bustillo, J., et al. Converting positive and negative symptom scores between PANSS and SAPS/SANS. Schizophr Res 152 (2014), 289–294.